• PNH Frontier

PNH Frontier


2017 No.4

【座談会 骨髄不全症候群のなかのPNH―病態研究の進歩と位置づけ―】

・ASH 2016(American Society of Hematology)
#1251 APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH):Phase I Data from Two Completed Studies in Healthy Volunteers
#2428 Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH):Interim Analysis of a Dose-Escalation Study
#3891 A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases:Interim Phase 1/2 Study Results
#1271 The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
#2450 Paroxysmal Nocturnal Hemoglobinuria Caused By PIGT Mutations;Atypical PNH
#2683 Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Haemoglobinuria (PNH) with Eculizumab:A UK Experience
#1042 T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways

診療ガイドライン UP-TO-DATE 掲載開始